Next steps in clinical validity assessment require the definition of a threshold for each BC subtype, a better characterization of TILs’ prognostic role in early HR+/HER2- BC, the definition of the prognostic value of TILs in advanced disease, and, lastly, the assessment of the predictive role of response to IO agents across all subtypes and all stages. Here, ERBB2 is linked to breast cancer.